Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: A simple, pragmatic approach for inhaled drug development

Journal of Applied Toxicology

Volumn 34, Issue 4, 2014, Pages 319-331

  Lewis, David J ^a   Williams, Thomas C ^b   Beck, Steven L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Tom C Williams Consultancy   (United Kingdom)

Author keywords

Accumulation; Adversity; Aetiology; Foamy; Inhaled; Macrophage; Pharmaceuticals

Indexed keywords

AMPHOPHILE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; FAT DROPLET; LUNG SURFACTANT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHOLIPASE C;

CRYSTAL; CRYSTALLIZATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; ENZYME INHIBITION; FOAMY MACROPHAGE; HUMAN; IMMUNE RESPONSE; INHALATION; LAMELLAR BODY; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS WALL; LYMPHOCYTIC INFILTRATION; LYSOSOME; MACROPHAGE ACTIVATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK;

RATTUS;

ACCUMULATION; ADVERSITY; AETIOLOGY; FOAMY; INHALED; MACROPHAGE; PHARMACEUTICALS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; DRUG DISCOVERY; FOAM CELLS; LUNG; MACROPHAGES, ALVEOLAR; MUSCARINIC ANTAGONISTS; NEUTROPHIL INFILTRATION; PHAGOCYTOSIS; RATS; SOLUBILITY;

EID: 84893639432     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2950     Document Type: Review

References (122)

1. Agassandian M, Mallampalli R. 2013. Surfactant phospholipid metabolism. Biochim. Biophys. Acta 1831(3):612-625.
2. Andreeva AV, Kutuzov MA, Yoyno-Yasenetskaya TA. 2007. Regulation of surfactant secretion in alveolar type II cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 293:L259-L271.
3. Baritussio AG, Magoon MW, Goerke JA, Clements JA. 1981. Precursor product relationship between rabbit type II cell lamellar bodies and alveolar surface-active material. Biochim. Biophys. Acta 666:382-393.
4. Barnes PJ. 1999. Effects of β-agonists on inflammatory cells. J. Allergy Clin. Immunol. 104:S10-S17.
5. Barone LR, Boyer S, Damewood J JR, Fikes J, Ciaccio PJ. 2012. Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies. J. Toxicol. 2012:308594.
6. 2-adrenoreceptor agonist. J. Med. Chem. 53(9):3675-3684.
7. Bignon J, Chaninian P, Feldmann G, Sapin C. 1975. Ultrastructural immunoperoxidase demonstration of autologous albumin in the alveolar capillary membrane and in the alveolar lining material in normal rats. J. Cell Biol. 64:503-509.
8. Brittan M, Barr L, Morris AC, Duffin R, Rossi F, Johnston S, Monro G, Anderson N, Rossi AG, McAuley DF, Haslett C, Hirani N, Dhaliwal K, Simpson AJ. 2012. A novel subpopulation of monocyte-like cells in the human lung after lipopolysaccharide inhalation. Eur. Respir. J. 40:206-214.
9. Brown DM, Dransfield I, Wetherill GZ, Donaldson K. 1993. LFA-1 and ICAM-1 in homotypic aggregation of rat alveolar macrophages: organic dust-mediated aggregation by a non-protein kinase C-dependent pathway. Am. J. Respir. Cell Mol. Biol. 9(2):205-212.
10. Byron PR. 1993. Physicochemical effects on lung disposition of pharmaceutical aerosols. Aerosl. Sci. Technol. 18:223-229.
11. Camus P, Mehendale HM. 1986. Pulmonary sequestration of amiodarone and desethylaminodarone. J. Pharmacol. Exp. Ther. 237:867-873.
12. Camus P, Joshi UM, Lockard VG, Petrini MF, Lentz DL, Mehendale HM. 1989. Effects of drug-induced pulmonary phospholipidosis on lung mechanics in rats. J. Appl. Physiol. 66(5):2437-2445.
13. Casarosa P, Boussou T, Germeyer S, Schnapp A, Gantner F, Pieper M. 2009. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Pharmacol. Exp. Ther. 330(2):660-668.
14. Cazzola M, Matera MG. 2009. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 43:757-769.
15. Cazzola M, Page CP, Calzetta L, Matera MG. 2012. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 64(3):450-504.
16. Chander A, Fisher AB. 1990. Regulation of surfactant secretion. Am. J. Physiol. Lung Cell. Mol. Physiol. 258(2):L241-L253.
17. Chatman LA, Morton D, Johnson TD, Anway SD. 2009. A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol. 37:997-1005.
18. Christmann U, Buechner VA, Witonsky SG, Hite RD. 2009. Role of lung surfactant in respiratory disease: current knowledge in large animal medicine. J. Vet. Intern. Med. 23:227-242.
19. Conn CA, Green FHY, Nikula KJ. 2000. Animal models of pulmonary infection in the compromised host: Potential usefulness for studying health effects of inhaled particles. Inhal. Toxicol. 12:783-827.
20. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. 1998. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Allergy Clin. Immunol. 101:S440-S446.
21. Dines GD, Bethell R, Daniel MJ. 1998. Preclinical development of low toxicity drugs. Drug Saf. 19(3):233-241.
22. Duffield JS. 2003. The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci. 104:27-38.
23. Dungworth DL, Ernst H, Nolte, T, Mohr U. 1992. Non-neoplastic lesions in the lungs. In: Pathobiology of the Aging Rat, Mohr U, Dungworth DL, Capen CC (eds). ILSI Press: Washington DC; 141-160.
24. Eckert H, Lux M, Lachmann B. 1983. The role of alveolar macrophages in surfactant turnover. Lung 161:213-218.
25. Ehrchen J, Steinmuller S, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, Nordhues U, Sorg C, Sunderkotter C, Roth J. 2007. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109(3):1265-1274.
26. Fagerland JA, Wall HG, Pandher K, LeRoy BE, Gagne G. 2012. Ultrastructural analysis in preclinical safety evaluation. Toxicol. Pathol. 40:391-402.
27. Ferin J 1982. Alveolar macrophage mediated pulmonary clearance suppressed by drug-induced phospholipidosis. Exp. Lung Res. 4:1-10.
28. Ferin J, Morehouse B. 1980. Lung clearance of particles in two strains of rats. Exp. Lung Res. 1:251-257.
29. Ferin J, Oberdorster G. 1992. Translocation of particles from pulmonary alveoli into the interstitium. J. Aerosol Med. 5(3):179-188.
30. Forbes A, Pickel M, Foroughian M, Yao L-J, Lewis J, Veldhuizen R. 2007. Alveolar macrophage depletion is associated with increased surfactant pool sizes in adult rats. J. Appl. Physiol. 103:637-645.
31. Forbes LR, Ducka B, Fehrenbach M, Hortobagyi L, Zhu X, Kierstein S, Sharma SK, Haczku A. 2010. Surfactant protein D (SP-D) binds to signal regulatory protein alpha (SIRP-α) on alveolar macrophages and dendritic cells and promotes allergen-induced lymph node directed migration. J. Allergy Clin. Immunol. 125 (2 Suppl. 1):AB126.
32. Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustasson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, Wolff RK. 2011. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Del. Rev. 63:69-87.
33. Fujisawa M, Okabe T, Murakami T, Takaku F. 1985. Corticosteroid receptor in type II pneumocytes of the rat. Life Sci. 38:413-416.
34. Fukushima T, Sekizawa K, Jin Y, Yamaya M, Sasaki H, Takishima T. 1993. Effects of β-adrenergic receptor activation on alveolar macrophage motility. Am. J. Physiol. Lung Cell. Mol. Physiol. 265 (9):L67-L72.
35. Gillett NA, Harmsen AG, Stegelmeier B. 1989. Translocation of particles by macrophages from lung to lymph nodes in rats. J. Aerosol Med. 2:29-37.
36. Gopinath C, Prentice DE, Lewis DJ. 1987. Atlas of Experimental Pathology. MTP Press; 22-29.
37. Gordon S 2002. Alternative activation of macrophages. Nat. Rev. 3:23-35.
38. Greaves P 2007. Respiratory tract. In: Histopathology of Preclinical Toxicity Studies: interpretation and relevance in drug safety evaluation. Elsevier: New York; 215-269.
39. Guth AM, Janssen WJ, Boslo CM, Crouch EC, Henson PM, Dow SW. 2009. Lung environment determines unique phenotype of alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:L936-L946.
40. Haagsmann HP, van Golde LMG. 1985. Lung surfactant and pulmonary toxicity. Lung 163:275-303.
41. Harmsen AG, Mason MJ, Muggenburg BA, Gillet NA, Jarpe MA, Bice DE. 1987. Migration of neutrophils from lung to tracheobronchial lymph node. J. Leuk. Biol. 41:95-103.
42. He Y, Xu Y, Zhang C, Gao X, Dykema KJ, Martin KR, Ke J, Hudson EA, Khoo SK, Resau JH, Alberts AS, MacKeigan JP, Furge KA, Xu HE. 2011. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal. 4:1-11.
43. Heid HW, Moll R, Schwetlick I, Rackwitz H-R, Keenan TW. 1998. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res. 294:309-321.
44. Holt PG, Warner LA, Papadimitriou JM. 1982. Alveolar macrophages: Functional heterogeneity within macrophage populations from rat lung. Aust. J. Exp. Biol. Med. Sci. 60(6):607-618.
45. Hughes AD, Chin KH, Dunham SL, Jasper JJ, Martin J, Steinfeld T. 2011. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoreceptor agonist (MABA) dual pharmacology molecules. Bioorg. Med. Chem. 21:1354-1358.
46. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Isshiki N, Momose D, Ouchi K. 2002. Improved inhalation behaviour of steroid KSR-592 in Vitro with Jethaler by polymorphic transformation to needle-like crystals (β-form). Pharm. Res. 19(10):1439-1445.
47. Joelson J, Kluger J, Cole S, Conway M. 1984. Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy. Chest 85(2):284-286.
48. 2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2:320-325.
49. Jones RM, Neef N. 2012. Intertpretation and prediction of inhaled drug particle accumulation in the lung and its associated toxicity. Xenobiotica 42:86-93.
50. Kannan R, Sarma JSM, Guha M, Venkataraman K. 1989. Tissue drug accumulation and ultrastructural changes during Amiodarone administration in rats. Fundam. Appl. Toxicol. 13:793-803.
51. Kapatou E, Skurlas A, Agelaki MG, Pantos, C, Koktlis TM, Malamou-Mitsi V. 2010. Amiodarone attenuates apoptosis, but induces phospholipidosis in rat alveolar epithelial cells. J. Physiol. Pharmacol. 61(6):671-677.
52. Kato T, Yashiro T, Murata Y, Herbert DC, Oshikawa K, Bando M, Ohno S, Sugiyama Y. 2003. Evidence that exogenous substances can be phagocytosed by alveolar epithelial cells and transported into blood capillaries. Cell Tissue Res. 311:47-51.
53. Keating GM. 2012. Tiotropium bromide inhalation powder. A review of its use in the management of chronic obstructive pulmonary disease. Drugs 72(2):273-300.
54. Kellner-Weibel G, Yancey WG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH. 1999. Crystallization of free cholesterol in model macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 19:1891-1898.
55. Klapwijk JC. 2011. Alveolar macrophages changes in response to inhaled drugs: Factors distinguishing adverse from non adverse effects. Annual HESI Emerging Issues Meeting, Alexandria, VA. Accessed 13 October 2011.
56. Koarai A, Traves PS, Fenwick PS, Brown SM, Chana KK, Russell REK, Nicholson AG, Barnes PJ, Donnelly LE. 2012. Expression of muscarinic receptors by human macrophages. Eur. Respir. J. 39:698-704.
57. Kobzik L, Huang S, Paulauskis JD, Godleski JJ. 1993. Particle opsonization and lung macrophage cytokine response. J. Immunol. 151(5):2753-2759.
58. Kornhuber J, Henkel AW, Groemer TW, Stadtler S, Welzel O, Tripal P, Rotter A, Bleich S, Trapp S. 2010. Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system. J. Cell. Physiol. 224:152-164.
59. Kramer BW, Jobe AH, Ikegami M. 2001. Exogenous surfactant changes the phenotype of alveolar macrophages in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L689-L694.
60. Kreyling WG. 2001. Particles are predominantly transported from the canine epithelium towards the interstitial spaces and not to larynx! Analogy to human lungs. Am. J. Respir. Crit. Care Med. 163:A166.
61. Krombach F, Munzing S, Allmeling A-M, Gerlach JT, Behr J, Dorger M. 1997. Cell size of alveolar macrophages: An interspecies comparison. Environ. Health Perspect. 105 (Suppl 5):1261-1263.
62. Lee KP, Henry NW, Trochimowicz HJ, Reinhardt CF. 1986. Pulmonary responses to impaired lung clearance following excessive TiO2 dust deposition. Environ. Res. 41:144-167.
63. Lehnert BE. 1990. Alveolar macrophages in a particle 'overload' condition. J. Aerosol Med. 3 (Suppl 1):S9-S29.
64. Lehnert BE. 1992. Pulmonary and thoracic macrophages subpopulations and clearance of particles from the lung. Environ. Health Perspect. 97:17-46.
65. Lehnert BE, Ferin J. 1983. Particle binding, phagocytosis, and plastic substrate adherence characteristics of alveolar macrophages from rats acutely treated with chlorphentermine. J. Reticuloendothel. Soc. 33(4):293-303.
66. Lewis DJ, McKevitt TP. 2013. Respiratory system. In: Toxicologic Pathology Nonclinical Safety Assessment. CRC Press, Taylor and Francis Group, 367-420.
67. Lowe R, Mussa HY, Nigsch F, Glen RC, Mitchell JBO. 2012. Predicting the mechanism of phospholipidosis. J. Cheminf. 4: 2.
68. Lusuardi M, Capelli A, Carli S, Tacconi MT, Salmona M, Donner CF. 1992. Role of surfactant in chronic obstructive pulmonary disease: therapeutic implications. Respiration 59(S1):28-32.
69. Macklin CC. 1955. Pulmonary sumps, dust accumulations, alveolar fluid and lymph vessels. Acta Anat. 23:1-33.
70. Mason RJ, Voelker DR. 1998. Regulatory mechanisms of surfactant secretion. Biochim. Biophys. Acta 1408:226-240.
71. Massaro D, Clerch L, Massaro GD. 1982. Surfactant secretion: evidence that cholinergic stimulation of secretion is indirect. Am. J. Physiol. Cell Physiol. 243(12):C39-C45.
72. Morrow PE. 1988. Possible mechanisms to explain overloading of the lungs. Fund. Appl. Toxicol. 10:369-384.
73. Murugan V, Peck MJ. 2009. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp. Lung Res. 35:439-485.
74. 2-adrenergic receptors. Am. J. Respir. Cell Mol. Biol. 38:127-134.
75. Oberdorster G, Ferin J, Morrow PE. 1992. Volumetric overloading of alveolar macrophages (AM): A possible basis for diminished AM-mediated particle clearance. Exp. Lung Res. 18:87-104.
76. Obert LA, Sobocinski GP, Bobrowski WF, Metz AL, Rolsma MD, Altrogge DM, Dunstan RW. 2007. An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats. Toxicol. Pathol. 35:728-734.
77. Ochs M 2010. The closer we look the more we see? Quantitative microscopic analysis of the pulmonary surfactant system. Cell. Physiol. Biochem. 25:27-40.
78. 2-adrenoceptor agonist. J. Asthma 35(5):401-408.
79. Ohmiya Y, Angevine LS, Mehendale HM. 1983. Effect of drug-induced phospholipidosis on pulmonary disposition of pneumophilic drugs. Drug Metab. Disp. 11:25-30.
80. Okazaki S, Yamazaki K, Tanmura T, Hoshiya T, Anabuki K, Tanaka H. 1992. A 13-week subcutaneous toxicity study of prednisalone farnesylate (PNF) in rats. J. Toxicol. Sci. 17:1-48.
81. Owen K 2013. Regulatory toxicology considerations for the development of inhaled pharmaceuticals. Drug Chem. Toxicol. 36:109-118.
82. Owen K, Beck SL, Damment SJP. 2010. The preclinical toxicology of salmeterol hydoxynaphthoate. Hum. Exp. Toxicol. 29(5):393-407.
83. Patton JS, Byron PR. 2007. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. 6:67-74.
84. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim K-J, Sakagami M, Vanbever R, Ehrhardt C. 2010. The particle has landed - characterising the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulmon. Drug Deliv. 23(Suppl. 2):S71-S87.
85. Pauluhn J 2005. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect. Toxicology 207:59-72.
86. Pellegatti M, Pagliarusco S. 2011. Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review. Expert Opin. Drug Metab. Toxicol. 7(2):137-146.
87. Perretti M, Wheller SK, Harris JG, Flower RJ. 1996. Modulation of ICAM-1 levels on U-937 cells and mouse macrophages by interleukin-1β and dexamethasone. Biochem. Biophys. Res. Commun. 223:112-117.
88. Plantier L, Besnard V, Xu Y, Ikegami M, Wert SE, Hunt AN, Postle AD, Whitsett JA. 2012. Activation of sterol-response element-binding proteins (SREBP) in alveolar type II cells enhances lipogenesis causing pulmonary lipotoxicity. J. Biol. Chem. 287(13):10099-10114.
89. Pozzi E 2007. Acebrophylline: an airway mucoregulator and anti-inflammatory agent. Monaldi Arch. Chest Dis. 67(2):106-115.
90. 2-agonist and anticholinergic drugs in the treatment of lung disease. Proc. Am. Thorac. Soc. 2:305-301.
91. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3:785-796.
92. Rasenack N, Steckel H, Muller BW. 2003. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J. Pharm. Sci. 92:35-44.
93. Ray NC, Alcaraz L. 2009. Muscarinic antagonist-β-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin. Ther. Pat. 19:1-12.
94. Reasor MJ. 1991. Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages. Res. Commun. Chem. Pathol. Pharmacol. 72(2):169-181.
95. Reasor MJ, Kacew S. 2001. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 226(9):825-830.
96. Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Banerji D. 2004. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. 44:37-47.
97. Rooney SA. 2001. Regulation of surfactant secretion. Comp. Biochem. Physiol. A 129:233-243.
98. Rooney SA, Young SL, Mendelson CR. 1994. Molecular and cellular processing of lung surfactant. FASEB J. 8:957-967.
99. Salonen RO, Matilla MJ. 1984. A 24-hour glucocorticoid treatment increases the number of β-adrenceptors in the rat lung. Acta Pharmacol. Toxicol. 55:425-428.
100. Slesinski RS, Turnbull D. 2008. Chronic inhalation exposure of rats for up to 104weeks to a non-carbon-based magnetite photocopying toner. Int. J. Toxicol. 27:427-439.
101. Snipes MB. 1995. Pulmonary retention of particles and fibres. In: Concepts in Inhalation Toxicology. Taylor and Francis: Washington DC; 193-227.
102. Sone S, Bucana C, Hoyer LC, Fidler IJ. 1981. Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes. Am. J. Pathol. 103:234-246.
103. Stout RD, Jiang C, Matta B, Tietzel L, Watkins SK, Suttles J. 2005. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175:342-349.
104. Sukpanichnant S, Hargrove NS, Kachintorn U, Manatsathit S, Chanchairujira T, Siritanaratkul N, Akaraviputh T, Thakerngpol K. 2000. Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. Am. J. Surg. Pathol. 24:129-135.
105. Tailor A, Das AM, Getting SJ, Flower RJ, Perretti M. 1997. Subacute treatment of rats with dexamethasone reduces ICAM-1 levels on circulating monocytes. Biochem. Biophys. Res. Commun. 231:675-678.
106. Tarling JD, Lin H-S, Hsu S. 1987. Self-renewal of alveolar macrophages: Evidence from radiation chimera studies. J. Leuk. Biol. 42:443-446.
107. Tolman JA, Nelson NA, Bosselmann S, Peters JI, Coalson JJ, Wiederhold NP, Williams RO. 2009. Dose tolerability of chronic inhaled voriconazole solution in rodents. Int. J. Pharm. 379:25-31.
108. Tran CL, Miller BG, Jones AD. 2003. Risk Assessment of Inhaled Particles using a Physiologically based Mechanistic Model. Health and Safety Executive Research Reports 141. HSE Books.
109. Tronde A, Norden B, Marchner H, Wendel A-K, Lennernas H, Hultkvist BU. 2003. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92(6):1216-1233.
110. 2-adrenergic receptors desensitize in response to in vivo administered β-agonist. Am. J. Physiol. Lung Cell. Mol. Physiol. 269(13):L709-L714.
111. Vacca GM, Randerath WJ, Gillissen A. 2011. Inhibition of granulocyte migration by tiotropium bromide. Respir. Res. 12:24.
112. Vakily M, Mehvar R, Brocks D. 2002. Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents. Ann. Pharmacother. 36:693-701.
113. Verma RK, Singh AK, Mohan M, Agrawal KA, Misra A 2011. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther. Deliv. 2(6):753-768.
114. Warheit DB, Hansen JF, Yuen IS, Kelly DP, Snajdr SI, Hartsky MA. 1997. Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Toxicol. Appl. Pharmacol. 145:10-22.
115. Weers JG, Bell J, Chan H-K, Cipolla D, Dunbar C, Hickey AJ, Smith IJ. 2010. Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulmon. Drug Deliv. 23:S5-S23.
116. Wessler I, Kirkpatrick CJ, Racke K. 1999. The cholinergic 'pitfall': acetylcholine: a universal cell molecule in biological systems, including humans. Clin. Exp. Pharmacol. Physiol. 26:198-205.
117. Williams CL, Hayes VY, Hummel AM, Tarara JE, Halsey TJ. 1993. Regulation of E-cadherin-mediated adhesion by muscarinic acetylcholine receptors in small cell lung carcinoma. J. Cell Biol. 121(3):643-654.
118. Yao W, Wang G, Zhu H, Sun Y, Zhao M. 2001. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic pulmonary obstructive disease. Chin. Med. J. 114:80-83.
119. Yeadon M. 2011. The paradox of respiratory R&D, and why 'inhaled-by-design' heralds a new dawn in asthma and chronic obstructive pulmonary disease treatments. Future Med. Chem. 3(13):1581-1583.
120. Young SL, Silbajoris R. 1986. Dexamethasone increases adult rat lung surfactant lipids. J. Appl. Physiol. 60(5):1665-1672.
121. 2-adrenergic agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD? Fund. Clin. Pharm. 26:118-134.
122. Zuo YY, Veldhuizen RAW, Neumann AW, Petersen NO, Possmayer F. 2008. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochim. Biophys. Acta 1778:1947-1977.